OncoMatch/Clinical Trials/NCT04872543
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
Is NCT04872543 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies ASTX727 for malignant peripheral nerve sheath tumors (mpnst).
Treatment: ASTX727 — The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: EED inactivating mutation
inactivating mutations in EED
Required: SUZ12 inactivating mutation
inactivating mutations in SUZ12
Required: EZH2 inactivating mutation
inactivating mutations in EZH2
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy — standard of care
have progressed on at least one line of standard of care systemic therapy
Cannot have received: anti-cancer therapy
Treatment with anti-cancer therapy within 14 days prior to the first dose of study drug therapy. For prior biological therapies, e.g., monoclonal antibodies with a half-life longer than 3 days, the interval must be at least 28 days prior to the first dose of study drug.
Lab requirements
Blood counts
ANC ≥ 1500/µL, platelets ≥ 75,000/µL, hemoglobin ≥ 9 g/dL (can be transfused to achieve this)
Kidney function
serum creatinine ≤ 1.5 x ULN
Liver function
total serum bilirubin ≤ 1.5 x ULN, serum AST (SGOT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor (liver metastases)), serum ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor (liver metastases))
Cardiac function
Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time > 1.5 x ULN. Patients on a stable maintenance regimen of anticoagulation therapy for at least 30 days prior to screening may have PT/INR measurements > 1.5 x ULN
Adequate renal, hepatic and hematologic function as the following: serum creatinine ≤ 1.5 x upper limit of normal (ULN), total serum bilirubin ≤ 1.5 x ULN, serum AST (SGOT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor (liver metastases)), serum ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor (liver metastases)), ANC ≥ 1500/µL, platelets ≥ 75,000/µL, and hemoglobin ≥ 9 g/dL(can be transfused to achieve this). Prothrombin time (PT), international normalized ratio (INR), and partial thromboplastin time > 1.5 x ULN. Patients on a stable maintenance regimen of anticoagulation therapy for at least 30 days prior to screening may have PT/INR measurements > 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04872543 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-cancer therapy disqualifies patients from enrollment.
Does this trial require EED?
Yes, EED inactivating mutation is a required biomarker for enrollment.
Does this trial require SUZ12?
Yes, SUZ12 inactivating mutation is a required biomarker for enrollment.
Does this trial require EZH2?
Yes, EZH2 inactivating mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify